236 related articles for article (PubMed ID: 31233760)
1. Identification of prognostic markers for hepatocellular carcinoma based on miRNA expression profiles.
Wang X; Gao J; Zhou B; Xie J; Zhou G; Chen Y
Life Sci; 2019 Sep; 232():116596. PubMed ID: 31233760
[TBL] [Abstract][Full Text] [Related]
2. Prognostic microRNA signature for estimating survival in patients with hepatocellular carcinoma.
Yerukala Sathipati S; Aimalla N; Tsai MJ; Carter T; Jeong S; Wen Z; Shukla SK; Sharma R; Ho SY
Carcinogenesis; 2023 Dec; 44(8-9):650-661. PubMed ID: 37701974
[TBL] [Abstract][Full Text] [Related]
3. Development of a necroptosis-related prognostic model for uterine corpus endometrial carcinoma.
Zhang Q; Luo Y; Zhang S; Huang Q; Liu G
Sci Rep; 2024 Feb; 14(1):4257. PubMed ID: 38383747
[TBL] [Abstract][Full Text] [Related]
4. The identification of N6-methyladenosine-related miRNAs predictive of hepatocellular carcinoma prognosis and immunotherapy efficacy.
Zou R; Liu Y; Qiu S; Lu Y; Chen Y; Yu H; Zhu H; Zhu W; Zhu L; Feng J; Han J
Cancer Biomark; 2023; 38(4):551-566. PubMed ID: 38007640
[TBL] [Abstract][Full Text] [Related]
5. Elucidating hepatocellular carcinoma progression: a novel prognostic miRNA-mRNA network and signature analysis.
Wang F; Kang X; Li Y; Lu J; Liu X; Yan H
Sci Rep; 2024 Feb; 14(1):5042. PubMed ID: 38424172
[TBL] [Abstract][Full Text] [Related]
6. Circulating Extracellular Vesicle-Derived microRNAs as Novel Diagnostic and Prognostic Biomarkers for Non-Viral-Related Hepatocellular Carcinoma.
Boonkaew B; Satthawiwat N; Pinjaroen N; Chuaypen N; Tangkijvanich P
Int J Mol Sci; 2023 Nov; 24(22):. PubMed ID: 38003232
[TBL] [Abstract][Full Text] [Related]
7. Association of serum microRNA expression in hepatocellular carcinomas treated with transarterial chemoembolization and patient survival.
Liu M; Liu J; Wang L; Wu H; Zhou C; Zhu H; Xu N; Xie Y
PLoS One; 2014; 9(10):e109347. PubMed ID: 25275448
[TBL] [Abstract][Full Text] [Related]
8. Identification of MicroRNAs as Breast Cancer Prognosis Markers through the Cancer Genome Atlas.
Chang JT; Wang F; Chapin W; Huang RS
PLoS One; 2016; 11(12):e0168284. PubMed ID: 27959953
[TBL] [Abstract][Full Text] [Related]
9. Role of miR
Cao Z; Zeng L; Wang Z; Zhou Y; Qian K
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1281-1295. PubMed ID: 38044639
[TBL] [Abstract][Full Text] [Related]
10. miR-21-5p promotes NASH-related hepatocarcinogenesis.
Rodrigues PM; Afonso MB; Simão AL; Islam T; Gaspar MM; O'Rourke CJ; Lewinska M; Andersen JB; Arretxe E; Alonso C; Santos-Laso Á; Izquierdo-Sanchez L; Jimenez-Agüero R; Eizaguirre E; Bujanda L; Pareja MJ; Prip-Buus C; Banales JM; Rodrigues CMP; Castro RE
Liver Int; 2023 Oct; 43(10):2256-2274. PubMed ID: 37534739
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel circulating miRNAs biomarkers for healthy obese and lean children.
Ma F; Cao D; Liu Z; Li Y; Ouyang S; Wu J
BMC Endocr Disord; 2023 Oct; 23(1):238. PubMed ID: 37904219
[TBL] [Abstract][Full Text] [Related]
12. Clustered microRNAs hsa-miR-221-3p/hsa-miR-222-3p and their targeted genes might be prognostic predictors for hepatocellular carcinoma.
Wang X; Liao X; Huang K; Zeng X; Liu Z; Zhou X; Yu T; Yang C; Yu L; Wang Q; Han C; Zhu G; Ye X; Peng T
J Cancer; 2019; 10(11):2520-2533. PubMed ID: 31258758
[No Abstract] [Full Text] [Related]
13. Utility of a microRNA panel in diagnosis and prognosis of hepatitis C-associated hepatocellular carcinoma.
ALrefai AA; Rizk SK; Khamis AK; Kasemy ZA; Habieb MSE
Lab Med; 2024 May; 55(3):310-319. PubMed ID: 37695165
[TBL] [Abstract][Full Text] [Related]
14. Systematic integration of molecular and clinical approaches in HCV-induced hepatocellular carcinoma.
Shabangu CS; Su WH; Li CY; Yu ML; Dai CY; Huang JF; Chuang WL; Wang SC
J Transl Med; 2024 Mar; 22(1):268. PubMed ID: 38475805
[TBL] [Abstract][Full Text] [Related]
15. miR-590-3p and Its Downstream Target Genes in HCC Cell Lines.
Elfar M; Amleh A
Anal Cell Pathol (Amst); 2019; 2019():3234812. PubMed ID: 31781476
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance.
Awan FM; Naz A; Obaid A; Ikram A; Ali A; Ahmad J; Naveed AK; Janjua HA
Sci Rep; 2017 Sep; 7(1):11448. PubMed ID: 28904393
[TBL] [Abstract][Full Text] [Related]
17. Increased hsa-miR-100-5p Expression Improves Hepatocellular Carcinoma Prognosis in the Asian Population with
Liao Z; Zhang Q; Yang L; Li H; Mo W; Song Z; Huang X; Wen S; Cheng X; He M
Cancers (Basel); 2023 Dec; 16(1):. PubMed ID: 38201556
[TBL] [Abstract][Full Text] [Related]
18. Monocytes subsets altered distribution and dysregulated plasma hsa-miR-21-5p and hsa-miR-155-5p in HCV-linked liver cirrhosis progression to hepatocellular carcinoma.
Hammad R; Eldosoky MA; Elmadbouly AA; Aglan RB; AbdelHamid SG; Zaky S; Ali E; Abd El Hakam FE; Mosaad AM; Abdelmageed NA; Kotb FM; Kotb HG; Hady AA; Abo-Elkheir OI; Kujumdshiev S; Sack U; Lambert C; Hamdy NM
J Cancer Res Clin Oncol; 2023 Nov; 149(17):15349-15364. PubMed ID: 37639012
[TBL] [Abstract][Full Text] [Related]
19. Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism Pathways.
Thurnherr T; Mah WC; Lei Z; Jin Y; Rozen SG; Lee CG
Sci Rep; 2016 Jan; 6():20065. PubMed ID: 26817861
[TBL] [Abstract][Full Text] [Related]
20. miRNome profiling analysis reveals novel hepatocellular carcinoma diagnostic, prognostic and treatment-related candidate biomarkers: post-hoc analysis of SORAMIC trial.
Morkunas E; Vaitkeviciute E; Inciuraite R; Kupcinskas J; Link A; Skieceviciene J; Alunni-Fabbroni M; Schütte K; Malfertheiner P; Varkalaite G; Ricke J
Dig Dis; 2024 Apr; ():. PubMed ID: 38657585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
